Business briefs: Endo; Allergan

Share this article:

Endo, which has been reportedly on the hunt for a buyer, named former Valeant president Rajiv De Silva president and CEO, effective March 18. The company's C-Suite shakeup has given a boost to its stock price, which hit its highest point since January 30, reported Bloomberg.

Allergan has settled a Botox-related lawsuit in Oklahoma  for an undisclosed amount, according to Bloomberg. The company was sued by the mother of a teenager who claimed the treatment, used for a leg condition, in this case, led to his death. She also alleged Allergan “promoted the drug for children despite a lack of regulatory approval for such use." This is not the first time the company has been accused of marketing the drug for unapproved uses—as Pharmalot noted in June, the company paid $600 million three years ago for off-label promotion.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.